Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis

Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis

Background: Recent studies have associated non-alcoholic fatty liver disease (NAFLD) with increased risk of cardiovascular disease, using tests of subclinical atherosclerosis. Aim: To evaluate the influence of NAFLD on subclinical atherosclerosis and coronary artery disease (CAD). Methods: We review...

Full description

Bibliographic Details
Main Authors:	Javier Ampuero, Rocío Gallego-Durán, Manuel Romero-Gómez
Format:	Article
Language:	English
Published:	Aran Ediciones
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	non-alcoholic fatty liver disease cardiovascular disease subclinical atherosclerosis steatohepatitis nash
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000100003&lng=en&tlng=en

Similar Items

Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice
by: Daniel Cabrera, et al.
Published: (2021-09-01)

Preventative and Therapeutic Effects of Astaxanthin on NAFLD
by: Nor Hafiza Sayuti, et al.
Published: (2023-08-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
by: Martina Colognesi, et al.
Published: (2020-07-01)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
by: Christoph Roderburg, et al.
Published: (2023-04-01)

Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
by: Christina-Maria Flessa, et al.
Published: (2022-12-01)

Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis
by: Constanze Hoebinger, et al.
Published: (2022-01-01)

Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD
by: Victoria Svop Jensen, et al.
Published: (2021-02-01)

The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis
by: Stamatina Vogli, et al.
Published: (2023-08-01)

Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
by: Clémence Rives, et al.
Published: (2020-12-01)

COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01)

Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Nelson Kei, et al.
Published: (2023-09-01)

Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages
by: Charles Drummer, et al.
Published: (2023-01-01)

Histopathological Association of Non-alcoholic Fatty Liver Disease With Coronary Artery Atherosclerosis Grade
by: Behnaz Gholami, et al.
Published: (2024-02-01)

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
by: Rodrigo Zamignan Carpi, et al.
Published: (2022-08-01)

Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study
by: Zhuojun Xin, et al.
Published: (2023-03-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01)

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
by: Yohwan Lim, et al.
Published: (2023-06-01)

Cohort study of cardiovascular risk in asymptomatic young adults: subclinical atherosclerosis and coronary calcium score
by: SADI POLETTO, et al.

Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
by: Alessandro Mantovani, et al.
Published: (2022-02-01)

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update
by: Chu-Jun Deng, et al.
Published: (2022-10-01)

Non Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure
by: Alabagi Abdulla, et al.
Published: (2016-04-01)

Alcohol or Not: A Review Comparing Initial Mechanisms, Contributing Factors, and Liver Transplantation Outcomes Between Alcoholic and Nonalcoholic Steatohepatitis
by: Chung-Shiung Wen, et al.
Published: (2018-09-01)

Risk factors of subclinical atherosclerosis of obesity women
by: N. N Shenkova, et al.
Published: (2017-06-01)

Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis
by: Xuefeng Ma, et al.
Published: (2020-01-01)

Association of Cardiovascular Health With Subclinical Disease and Incident Events: The Multi‐Ethnic Study of Atherosclerosis
by: Tamar S. Polonsky, et al.
Published: (2017-03-01)

Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
by: Min-Kyu Kang, et al.
Published: (2021-05-01)

Metabolic health phenotype better predicts subclinical atherosclerosis than body mass index-based obesity phenotype in the non-alcoholic fatty liver disease population
by: Yaqin Wang, et al.
Published: (2023-09-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

Work Shift, Lifestyle Factors, and Subclinical Atherosclerosis in Spanish Male Workers: A Mediation Analysis
by: José L. Peñalvo, et al.
Published: (2021-03-01)

Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity
by: Barbara Barbaro, et al.
Published: (2018-10-01)

The impact of diabetes and subclinical hypothyroidism association with coronary artery calcium: results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
by: Aída de Melo Spilack, et al.
Published: (2024-02-01)

Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
by: Deniz Tümen, et al.
Published: (2022-12-01)

Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
by: Annelise M. Poss, et al.
Published: (2020-07-01)

Editorial: New Insights Into Understanding and Managing NAFLD
by: Óscar Escribano, et al.
Published: (2021-11-01)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
by: Eleftheria Galatou, et al.
Published: (2022-05-01)

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
by: Ye Eun Cho, et al.
Published: (2023-03-01)

Serum Endocan Levels and Subclinical Atherosclerosis in Behçet’s Syndrome
by: Nassef EM, et al.
Published: (2022-08-01)